From a pathological perspective, METTL1 is overexpressed in a wide variety of cancers such as lung (LUAD) (73), prostate (PCa) (57,74), bladder (BCa) (75), head and neck squamous cell carcinoma (HNSCC) (76), breast cancer (BC), glioblastoma (GBM), melanoma, acute myelogenous leukemia (AML) (70), hepatocellular carcinoma (HCC) (77), intrahepatic cholangiocarcinoma (ICC) (71), osteosarcoma (78), nasopharyngeal carcinoma (NPC) (79) and esophageal squamous cellk carcinoma (ESCC) (72). Here, METTL1 is linked to posterior cortical atrophy.